Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
symbols : AMRX crawled time : 14:00 save search
Amneal Announces U.S. FDA Approval of Over-the-Counter Naloxone Hydrochloride Nasal Spray for Emergency Treatment of an Opioid Overdose
Published: 2024-04-24 (Crawled : 14:00) - biospace.com/
AMRX | $6.05 12.04% 11.04% 0
|
Health Technology
|
| O: 6.67%
H: 6.08%
C: 5.03%
fda opioid approval treatment for spray
Amneal Launches PEMRYDI RTU®, the First Ready-to-Use Version of Important Oncology Injectable Medicine
Published: 2024-04-16 (Crawled : 14:00) - biospace.com/
AMRX | $6.05 12.04% 11.04% 0
|
Health Technology
|
| O: -1.08%
H: 1.09%
C: -0.55%
rtu first
Amneal Enters into Exclusive European Licensing Agreement with Zambon Biotech for IPX203
Published: 2024-02-27 (Crawled : 14:00) - biospace.com/
AMRX | $6.05 12.04% 11.04% 0
|
Health Technology
|
| O: -1.89%
H: 1.75%
C: 0.0%
ipx203 biotech agreement
Amneal Adds Two Denosumab Biosimilars to U.S. Pipeline, Expanding Oncology Portfolio
Published: 2023-10-12 (Crawled : 14:00) - biospace.com/
AMRX | $6.05 12.04% 11.04% 0
|
Health Technology
|
| O: 0.24%
H: 0.95%
C: -9.74%
Amneal Receives U.S. FDA Approval for Lisdexamfetamine Dimesylate
Published: 2023-09-06 (Crawled : 14:00) - biospace.com/
AMRX | $6.05 12.04% 11.04% 0
|
Health Technology
|
| O: 3.14%
H: 0.0%
C: -6.09%
fda approval
Generic Drugs Market is Projected To Reach USD 835.7 Billion By 2032, Growing at A CAGR of 8.1% | Valuates Reports
Published: 2023-08-09 (Crawled : 14:00) - prnewswire.com
GLAXF | News | $19.54 -3.77% -14.18% 0
|
Health Technology
|
| O: 1.92%
H: 0.0%
C: 0.0%
TEVA | $13.01 -0.31% 7.1M
|
Health Technology
|
| O: 0.1%
H: 1.33%
C: -1.12%
GSK | News | $40.86 -0.92% 0.91% 11K
|
Health Technology
|
| O: 0.14%
H: 0.8%
C: 0.43%
AMRX | $6.05 12.04% 11.04% 0
|
Health Technology
|
| O: 0.0%
H: 0.67%
C: -5.58%
reach growing market
Amneal Launches Third Biosimilar with FYLNETRA™ (pegfilgrastim-pbbk) in the United States
Published: 2023-05-16 (Crawled : 14:00) - biospace.com/
AMRX | $6.05 12.04% 11.04% 0
|
Health Technology
|
| O: -0.99%
H: 4.99%
C: 1.5%
biosimilar
Amneal Reports Fourth Quarter and Full Year 2022 Financial Results
Published: 2023-03-02 (Crawled : 14:00) - biospace.com/
AMRX | $6.05 12.04% 11.04% 0
|
Health Technology
|
| O: -1.91%
H: 0.0%
C: -2.93%
year financial results
Amneal Announces U.S. FDA Filing Acceptance of Abbreviated New Drug Application for Naloxone Hydrochloride Nasal Spray, USP, 4mg
Published: 2023-03-02 (Crawled : 14:00) - biospace.com/
AMRX | $6.05 12.04% 11.04% 0
|
Health Technology
|
| O: -1.91%
H: 0.0%
C: -2.93%
fda drug application
Amneal to Participate at Upcoming Investor Conferences
Published: 2022-11-23 (Crawled : 14:00) - biospace.com/
AMRX | $6.05 12.04% 11.04% 0
|
Health Technology
|
| O: 0.85%
H: 2.52%
C: 1.68%
Amneal Announces U.S. FDA Filing Acceptance of New Drug Application for IPX203 for the Treatment of Parkinson’s Disease
Published: 2022-11-11 (Crawled : 14:00) - biospace.com/
AMRX | $6.05 12.04% 11.04% 0
|
Health Technology
|
| O: 0.0%
H: 4.62%
C: 3.36%
ipx203 treatment fda drug disease application parkinson’s
Amneal Expands Injectables Portfolio with 4 New Products
Published: 2022-02-17 (Crawled : 14:00) - biospace.com/
AMRX | $6.05 12.04% 11.04% 0
|
Health Technology
|
| O: -0.41%
H: 0.8%
C: -1.66%
new product
TherapeuticsMD Settles U.S. Patent Litigation with Amneal for BIJUVA® (Estradiol and Progesterone) — Allowing for a May 25, 2032 Generic Entry Date
Published: 2021-12-08 (Crawled : 14:00) - biospace.com/
AMRX | $6.05 12.04% 11.04% 0
|
Health Technology
|
| O: 0.0%
H: 0.12%
C: -0.47%
TXMD | News | $1.92 2.13% -0.27% 15K
|
Health Technology
|
| O: 8.64%
H: 7.27%
C: 5.14%
bijuva patent therapeutics
Amneal Receives Approval for Difluprednate Ophthalmic Emulsion
Published: 2021-11-19 (Crawled : 14:00) - biospace.com/
AMRX | $6.05 12.04% 11.04% 0
|
Health Technology
|
| O: -1.31%
H: 4.08%
C: 1.99%
approval ophthalmic emulsion
Amneal to Report Second Quarter 2021 Results on August 9, 2021
Published: 2021-07-15 (Crawled : 14:00) - biospace.com/
AMRX | $6.05 12.04% 11.04% 0
|
Health Technology
|
| O: -0.22%
H: 1.34%
C: -2.68%
results
Amneal Reports First Quarter 2021 Financial Results
Published: 2021-05-07 (Crawled : 14:00) - biospace.com/
AMRX | $6.05 12.04% 11.04% 0
|
Health Technology
|
| O: 1.21%
H: 0.34%
C: -11.11%
financial results results report
Amneal to Report Fourth Quarter & Full Year 2020 Results on February 26, 2021
Published: 2021-02-04 (Crawled : 14:00) - biospace.com/
AMRX | $6.05 12.04% 11.04% 0
|
Health Technology
|
| O: -0.81%
H: 5.33%
C: 4.3%
results
Gainers vs Losers
| 61% | 39% |
Top 10 Gainers
BOF | $2.08 77.78% 39.06% 110M
|
BHIL | $0.1793 -4.37% 19.24% 340K
|
Agriculture, Forestry, Fishing ...
UMAC | $1.48 -1.33% 14.87% 20K
|
CI | $352.28 -0.11% 13.53% 2
|
Health Services
CIG.C | $2.89 -1.37% 12.8% 2.3K
|
n/a
MTH | $154.69 -2.21% 12.68% 450K
|
Consumer Durables
BMTX 4 | $1.545 0.98% 10.03% 2.5K
|
Information
TAL | $12.26 0.57% 9.22% 12M
|
Consumer Services
ASXC | $0.243 -2.41% 7.0% 1.1M
|
Manufacturing
IHT P | $1.3712 0.82% 6.48% 0
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.